Nuclear factor-κB mediates the inhibitory effects of tumor necrosis factor-α on growth hormone-inducible gene expression in liver

Endocrinology

Volumn 149, Issue 12, 2008, Pages 6378-6388

  Buzzelli, Mark D ^a   Nagarajan, Murali ^a   Radtka, John F ^a   Shumate, Margaret L ^a   Navaratnarajah, Maithili ^a   Lang, Charles H ^a   Cooney, Robert N ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYCLOHEXIMIDE; FUMONISIN B1; HUMAN GROWTH HORMONE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; SPHINGOMYELIN PHOSPHODIESTERASE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; GROWTH HORMONE; GUANOSINE 3',5' POLYPHOSPHATE SYNTHETASES; GUANOSINE 3',5'-POLYPHOSPHATE SYNTHETASES; LIGASE; STAT5 PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; EXPRESSION VECTOR; GENE CONSTRUCT; GENE DELETION; GENE EXPRESSION; GENETIC TRANSFECTION; HORMONE ACTION; INHIBITION KINETICS; LIVER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; STIMULATION; ANIMAL; CELL LINE; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; GENE EXPRESSION; GROWTH HORMONE; LIGASES; LIVER; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RATS; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57349099190     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-1574     Document Type: Article

References (53)

1. Gettins PG 2002 Serpin structure, mechanism, and function. Chem Rev 102:4751-4804
2. Dahn MS, Lange MP 1998 Systemic and splanchnic metabolic response to exogenous human growth hormone. Surgery 123:528-538
3. Dahn MS, Lange MP, Jacobs LA 1988 Insulinlike growth factor 1 production is inhibited in human sepsis. Arch Surg 123:1409-1414
4. Ballinger AB, Camacho-Hubner C, Croft NM 2001 Growth failure and intestinal inflammation. QJM 94:121-125
5. Yumet G, Shumate ML, Bryant DP, Lang CH, Cooney RN 2006 Hepatic growth hormone resistance during sepsis is associated with increased suppressors of cytokine signaling expression and impaired growth hormone signaling. Crit Care Med 34:1420-1427
6. Yumet G, Shumate ML, Bryant P, Lin CM, Lang CH, Cooney RN 2002 Tumor necrosis factor mediates hepatic growth hormone resistance during sepsis. Am J Physiol Endocrinol Metab 283:E472-E481
7. Ahmed T, Yumet G, Shumate M, Lang CH, Rotwein P, Cooney RN 2006 Tumor necrosis factor inhibits growth hormone-mediated gene expression in hepatocytes. Am J Physiol Gastrointest Liver Physiol 291:G35-G44
8. Wullaert A, van Loo G, Heyninck K, Beyaert R 2007 Hepatic tumor necrosis factor signaling and nuclear factor-κB: effects on liver homeostasis and beyond. Endocr Rev 28:365-386
9. Ghosh S, Karin M 2002 Missing pieces in the NF-κB puzzle. Cell 109(Suppl):S81-S96
10. Simar-Blanchet AE, Legraverend C, Thissen JP, Le Cam A 1998 Transcription of the rat serine protease inhibitor 2.1 gene in vivo: correlation with GAGA box promoter occupancy and mechanism of cytokine-mediated down-regulation. Mol Endocrinol 12:391-404
11. Chen YQ, Sengchanthalangsy LL, Hackett A, Ghosh G 2000 NF-κB p65 (RelA) homodimer uses distinct mechanisms to recognize DNA targets. Structure 8:419-428
12. Liu SF, Malik AB 2006 NF-κB activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290:L622-L645
13. Karin M, Ben-Neriah Y 2000 Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 18:621-663
14. Hayden MS, Ghosh S 2004 Signaling to NF-κB. Genes Dev 18:2195-2224
15. Bonizzi G, Karin M 2004 The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280-288
16. Chen LF, Greene WC 2003 Regulation of distinct biological activities of the NF-κB transcription factor complex by acetylation. J Mol Med 81:549-557
17. Sun S, Elwood J, Greene WC 1996 Both amino- and carboxyl-terminal sequences within IκBα regulate its inducible degradation. Mol Cell Biol 16:1058-1065
18. Good LF, Maggirwar SB, Kealiher A, Uhlik M, Sun SC 1996 Multiple structural domains within IκBα are required for its inducible degradation by both cytokines and phosphatase inhibitors. Biochem Biophys Res Commun 223:123-128
19. Ganchi PA, Sun SC, Greene WC, Ballard DW 1993 A novel NF-κB complex containing p65 homodimers: implications for transcriptional control at the level of subunit dimerization. Mol Cell Biol 13:7826-7835
20. Ballard DW, Dixon EP, Peffer NJ, Bogerd H, Doerre S, Stein B, Greene WC 1992 The 65-kDa subunit of human NF-κB functions as a potent transcriptional activator and a target for v-Rel-mediated repression. Proc Natl Acad Sci USA 89:1875-1879
21. Ganchi PA, Sun SC, Greene WC, Ballard DW 1992 IκB/MAD-3 masks the nuclear localization signal of NF-κB p65 and requires the transactivation domain to inhibit NF-κB p65 DNA binding. Mol Biol Cell 3:1339-1352
22. Woelfle J, Chia DJ, Rotwein P 2003 Mechanisms of growth hormone (GH) action. Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation. J Biol Chem 278:51261-51266
23. Hall LJ, Kajimoto Y, Bichell D, Kim SW, James PL, Counts D, Nixon LJ, Tobin G, Rotwein P 1992 Functional analysis of the rat insulin-like growth factor I gene and identification of an IGF-I gene promoter. DNA Cell Biol 11:301-313
24. Woodworth CD, Isom HC 1987 Regulation of albumin gene expression in a series of rat hepatocyte cell lines immortalized by simian virus 40 and maintained in chemically defined medium. Mol Cell Biol 7:3740-3748
25. Kempe KC, Isom HC, Greene FE 1995 Responsiveness of an SV40-immortalized hepatocyte cell line to growth hormone. Biochem Pharmacol 49:1091-1098
26. Strle K, Broussard SR, McCusker RH, Shen WH, Johnson RW, Freund GG, Dantzer R, Kelley KW 2004 Proinflammatory cytokine impairment of insulin-like growth factor I-induced protein synthesis in skeletal muscle myoblasts requires ceramide. Endocrinology 145:4592-4602
27. Marderstein EL, Bucher B, Guo Z, Feng X, Reid K, Geller DA 2003 Protection of rat hepatocytes from apoptosis by inhibition of c-Jun N-terminal kinase. Surgery 134:280-284
28. Shumate ML, Yumet G, Ahmed TA, Cooney RN 2005 Interleukin-1 inhibits the induction of insulin-like growth factor-I by growth hormone in CWSV-1 hepatocytes. Am J Physiol Gastrointest Liver Physiol 289:G227-G239
29. Chia DJ, Ono M, Woelfle J, Schlesinger-Massart M, Jiang H, Rotwein P 2006 Characterization of distinct Stat5b binding sites that mediate growth hormone-stimulated IGF-I gene transcription. J Biol Chem 281:3190-3197
30. Woelfle J, Billiard J, Rotwein P 2003 Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b. J Biol Chem 278:22696-22702
31. Gronowski AM, Le Stunff C, Rotwein P 1996 Acute nuclear actions of growth hormone (GH): cycloheximide inhibits inducible activator protein-1 activity, but does not block GH-regulated signal transducer and activator of transcription activation or gene expression. Endocrinology 137:55-64
32. Flores-Morales A, Greenhalgh CJ, Norstedt G, Rico-Bautista E 2006 Negative regulation of growth hormone receptor signaling. Mol Endocrinol 20:241-253
33. Ahmed TA, Buzzelli MD, Lang CH, Capen J, Shumate ML, Navaratnarajah M, Nagarajan M, Cooney RN 2007 Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes. Am J Physiol Gastrointest Liver Physiol 292:G1793-G1803
34. Chow JC, Ling PR, Qu Z, Laviola L, Ciccarone A, Bistrian BR, Smith RJ 1996 Growth hormone stimulates tyrosine phosphorylation of JAK2 and STAT5, but not insulin receptor substrate-1 or SHC proteins in liver and skeletal muscle of normal rats in vivo. Endocrinology 137:2880-2886
35. Davey HW, Xie T, McLachlan MJ, Wilkins RJ, Waxman DJ, Grattan DR 2001 STAT5b is required for GH-induced liver IGF-I gene expression. Endocrinology 142:3836-3841
36. Bergad PL, Shih HM, Towle HC, Schwarzenberg SJ, Berry SA 1995 Growth hormone induction of hepatic serine protease inhibitor 2.1 transcription is mediated by a Stat5-related factor binding synergistically to two γ-activated sites. J Biol Chem 270:24903-24910
37. Park SH, Yamashita H, Rui H, Waxman DJ 2001 Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT5a) and STAT5b: impact on STAT5 transcriptional activity. Mol Endocrinol 15:2157-2171
38. Pircher TJ, Petersen H, Gustafsson JA, Haldosen LA 1999 Extracellular signal-regulated kinase (ERK) interacts with signal transducer and activator of transcription (STAT) 5a. Mol Endocrinol 13:555-565
39. Pircher TJ, Flores-Morales A, Mui AL, Saltiel AR, Norstedt G, Gustafsson JA, Haldosen LA 1997 Mitogen-activated protein kinase kinase inhibition decreases growth hormone stimulated transcription mediated by STAT5. Mol Cell Endocrinol 133:169-176
40. Wyszomierski SL, Yeh J, Rosen JM 1999 Glucocorticoid receptor/signal transducer and activator of transcription 5 (STAT5) interactions enhance STAT5 activation by prolonging STAT5 DNA binding and tyrosine phosphorylation. Mol Endocrinol 13:330-343
41. Litterst CM, Kliem S, Lodrini M, Pfitzner E 2005 Coactivators in gene regulation by STAT5. Vitam Horm 70:359-386
42. Litterst CM, Kliem S, Marilley D, Pfitzner E 2003 NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the FDL motif in the α-helical region of the STAT5 transactivation domain. J Biol Chem 278:45340-45351
43. Cui TX, Piwien-Pilipuk G, Huo JS, Kaplani J, Kwok R, Schwartz J 2005 Endogenous CCAAT/enhancer binding protein β and p300 are both regulated by growth hormone to mediate transcriptional activation. Mol Endocrinol 19:2175-2186
44. Pfitzner E, Jahne R, Wissler M, Stoecklin E, Groner B 1998 p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response. Mol Endocrinol 12:1582-1593
45. Mittanck DW, Kim SW, Rotwein P 1997 Essential promoter elements are located within the 5′ untranslated region of human insulin-like growth factor-I exon I. Mol Cell Endocrinol 126:153-163
46. Wang Y, Jiang H 2005 Identification of a distal STAT5-binding DNA region that may mediate growth hormone regulation of insulin-like growth factor-I gene expression. J Biol Chem 280:10955-10963
47. Schmitz ML, Baeuerle PA 1991 The p65 subunit is responsible for the strong transcription activating potential of NF-κB. EMBO J 10:3805-3817
48. Schmitz ML, dos Santos Silva MA, Altmann H, Czisch M, Holak TA, Baeuerle PA 1994 Structural and functional analysis of the NF-κB p65 C terminus. An acidic and modular transactivation domain with the potential to adopt an α-helical conformation. J Biol Chem 269:25613-25620
49. Schmitz ML, dos Santos Silva MA, Baeuerle PA 1995 Transactivation domain 2 (TA2) of p65 NF-κB. Similarity to TA1 and phorbol ester-stimulated activity and phosphorylation in intact cells. J Biol Chem 270:15576-15584
50. Geymayer S, Doppler W 2000 Activation of NF-κB p50/p65 is regulated in the developing mammary gland and inhibits STAT5-mediated β-casein gene expression. FASEB J 14:1159-1170
51. Luo G, Yu-Lee L 2000 Stat5b inhibits NFκB-mediated signaling. Mol Endocrinol 14:114-123
52. Sun SC, Maggirwar SB, Harhaj EW, Uhlik M 1999 Binding of c-Rel to STAT5 target sequences in HTLV-I-transformed T cells. Oncogene 18:1401-1409
53. Chen Y, Sun D, Krishnamurthy VM, Rabkin R 2007 Endotoxin attenuates growth hormone-induced hepatic insulin-like growth factor I expression by inhibiting JAK2/STAT5 signal transduction and STAT5b DNA binding. Am J Physiol Endocrinol Metab 292:E1856-E1862